BioCryst Pharmaceuticals Inc. Revenue 2009–2025
BioCryst Pharmaceuticals Inc. annual/quarterly revenue history and growth rate from 2009 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- BioCryst Pharmaceuticals Inc. revenue for the quarter ending March 31, 2026 was 156.4 M, a 7.48% increase year-over-year.
- BioCryst Pharmaceuticals Inc. revenue for the twelve months ending March 31, 2026 was 624.7 M, a 53.90% increase year-over-year.
- BioCryst Pharmaceuticals Inc. annual revenue for 2025 was 874.8 M, a 94.10% increase from 2024.
- BioCryst Pharmaceuticals Inc. annual revenue for 2024 was 450.7 M, a 36.00% increase from 2023.
- BioCryst Pharmaceuticals Inc. annual revenue for 2023 was 331.4 M, a 22.37% increase from 2022.
- BioCryst Pharmaceuticals Inc. annual revenue for 2022 was 270.8 M.
BioCryst Pharmaceuticals Inc. (BCRX) — Frequently Asked Questions
BioCryst Pharmaceuticals Inc. (BCRX) is a publicly traded US company. It has a market capitalization of $1.83B. In fiscal 2025 it reported revenue of $875M and net income of $264M. Explore BCRX's stock price, financial statements, earnings history, margins and key ratios below.
What is BioCryst Pharmaceuticals Inc.'s market cap?
BioCryst Pharmaceuticals Inc. (BCRX) has a market capitalization of $1.83B.
What is the BCRX stock price?
BCRX trades at $8.37 (+2.14% on the day).
How much revenue does BioCryst Pharmaceuticals Inc. make?
BioCryst Pharmaceuticals Inc. reported revenue of $875M in fiscal 2025.
Is BCRX profitable?
In fiscal 2025, BioCryst Pharmaceuticals Inc. reported net income of $264M.